Abstract
Low oxygen condition (hypoxia) is considered a hallmark of rapidly growing solid tumors. The presence of hypoxia renders tumor cells resistant to conventional chemo- and radio-therapy selecting a more malignant and invasive phenotype, and playing a negative role in patient prognosis. This commentary wishes to recognize the 2019 Nobel Prize in Medicine awarded to three physicians-scientists, Prof. William G. Kaelin Jr., Prof. Sir Peter J. Ratcliffe, and Prof. Gregg L. Semenza, for their discovery of the mechanisms mediating cell ability to sense and adapt to changes in oxygen availability. Their studies established the basis for our understanding of the role of hypoxia in a variety of diseases, including anemia, renal failure, cardiovascular disease, metabolic diseases, and cancer, paving the way for new promising therapeutic strategies through the development of drugs that can either activate or block the oxygen-sensing machinery.
| Original language | English |
|---|---|
| Number of pages | 1 |
| Journal | Journal of experimental & clinical cancer research : CR |
| Volume | 39 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 10 2020 |
Fingerprint
Keywords
- Angiogenesis
- Cancer
- HIF
- Hypoxia
- Metastasis
- Oxygen sensing
- VEGF
- VHL
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Targeting hypoxia in tumor : a new promising therapeutic strategy. / Bosco, Maria Carla; D'Orazi, Gabriella; Del Bufalo, Donatella.
In: Journal of experimental & clinical cancer research : CR, Vol. 39, No. 1, 10.01.2020.Research output: Contribution to journal › Editorial
}
TY - JOUR
T1 - Targeting hypoxia in tumor
T2 - a new promising therapeutic strategy
AU - Bosco, Maria Carla
AU - D'Orazi, Gabriella
AU - Del Bufalo, Donatella
PY - 2020/1/10
Y1 - 2020/1/10
N2 - Low oxygen condition (hypoxia) is considered a hallmark of rapidly growing solid tumors. The presence of hypoxia renders tumor cells resistant to conventional chemo- and radio-therapy selecting a more malignant and invasive phenotype, and playing a negative role in patient prognosis. This commentary wishes to recognize the 2019 Nobel Prize in Medicine awarded to three physicians-scientists, Prof. William G. Kaelin Jr., Prof. Sir Peter J. Ratcliffe, and Prof. Gregg L. Semenza, for their discovery of the mechanisms mediating cell ability to sense and adapt to changes in oxygen availability. Their studies established the basis for our understanding of the role of hypoxia in a variety of diseases, including anemia, renal failure, cardiovascular disease, metabolic diseases, and cancer, paving the way for new promising therapeutic strategies through the development of drugs that can either activate or block the oxygen-sensing machinery.
AB - Low oxygen condition (hypoxia) is considered a hallmark of rapidly growing solid tumors. The presence of hypoxia renders tumor cells resistant to conventional chemo- and radio-therapy selecting a more malignant and invasive phenotype, and playing a negative role in patient prognosis. This commentary wishes to recognize the 2019 Nobel Prize in Medicine awarded to three physicians-scientists, Prof. William G. Kaelin Jr., Prof. Sir Peter J. Ratcliffe, and Prof. Gregg L. Semenza, for their discovery of the mechanisms mediating cell ability to sense and adapt to changes in oxygen availability. Their studies established the basis for our understanding of the role of hypoxia in a variety of diseases, including anemia, renal failure, cardiovascular disease, metabolic diseases, and cancer, paving the way for new promising therapeutic strategies through the development of drugs that can either activate or block the oxygen-sensing machinery.
KW - Angiogenesis
KW - Cancer
KW - HIF
KW - Hypoxia
KW - Metastasis
KW - Oxygen sensing
KW - VEGF
KW - VHL
UR - http://www.scopus.com/inward/record.url?scp=85077765664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077765664&partnerID=8YFLogxK
U2 - 10.1186/s13046-019-1517-0
DO - 10.1186/s13046-019-1517-0
M3 - Editorial
C2 - 31924239
AN - SCOPUS:85077765664
VL - 39
JO - Journal of Experimental and Clinical Cancer Research
JF - Journal of Experimental and Clinical Cancer Research
SN - 0392-9078
IS - 1
ER -